Biosimilar Interchangeability: NOR-SWITCH-Type Study Not Enough For US FDA
Executive Summary
Norwegian single-transition study would not satisfy agency's requirements for demonstrating interchangeability but could boost patient confidence in general concept of switching between reference product and biosimilar.
You may also be interested in...
Kanjinti’s Path To Market Complicated By GMP Issues, Reference Product Drift
US FDA licensure of Amgen’s biosimilar to Herceptin was delayed by a complete response letter citing product manufacturing facility deficiencies; review documents discuss how drift in Genentech's reference product impacted the biosimilar program's analytical and clinical data.
Biosimilar Interchangeability: How To Design A Multiple-Switch Study
US FDA guidance lays out two types of study design recommendations: a dedicated study to demonstrate interchangeability, and an integrated study intended to support determinations of both biosimilarity and interchangeability.
Biosimilar Interchangeability: How To Design A Multiple-Switch Study
US FDA guidance lays out two types of study design recommendations: a dedicated study to demonstrate interchangeability, and an integrated study intended to support determinations of both biosimilarity and interchangeability.